Download PDF
Exp Clin Endocrinol Diabetes 2012; 120(09): 524-528
DOI: 10.1055/s-0032-1323807
Article
© J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York

Mental Health Status and Factors that Influence the Course of Graves’ Disease and Antithyroid Treatments

D. Y. Chen
1   Department of Nuclear Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
,
P. F. Schneider
2   Center of Internal Medicine, University Clinic, Clinic for Nuclear Medicine, Würzburg, Germany
,
X. S. Zhang
1   Department of Nuclear Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
,
Z. M. He
3   Internal Medicine of The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
,
J. Jing
4   The School of Public Health, Sun Yat-sen University, Guangzhou, China
,
T. H. Chen
1   Department of Nuclear Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
› Author Affiliations
Further Information

Publication History

received 07 February 2012
first decision 03 July 2012

accepted 24 August 2012

Publication Date:
15 October 2012 (online)

Also available at
    Permissions and Reprints

Abstract

Aims:

Biological, psychological and social factors may interact with the mental health status of Graves’ disease (GD) patients before and after antithyroid drug (ATD) treatment. Our aim was to quantify the impact of supportive and risk factors after recovery from GD which may enhance cure rates.

Patients and Methods:

300 patients were recruited for a 6-year prospective cohort study. Before and after treatment, we assessed the impact of biopsychosocial factors on the success of ATD treatment and mental health using the Symptom Checklist 90, the Eysenck Personality Questionnaire, the Life Event Scale, Simplified Coping Styles and the Perceived Social Support Scale. The patients routinely received ATD at least over 18 months. End-point was defined as cured (at least 2 years without a relapse after the withdrawal of ATD), otherwise as not cured.

Results:

Regression analysis explained 80.5% of the influences affecting mental health. The odds ratios (OR) revealed positive coping styles (OR: 2.90, 95% CI, 1.09–7.68), negative events (OR: 1.04, 95% CI, 1.01–1.07) and social support (OR: 5.10, 95% CI, 2.77–9.40) as protective factors, predicting a cure for GD patients. These variables explained 61.7% of the influences leading to a cure or no cure. Large thyroid volume was a risk factor, predicting failure (OR: 0.865, 95% CI, 0.83–0.90, P<0.000).

Conclusions:

Enhancing positive coping strategies and social support is important to improve mental health in GD patients, to avoid compromising work-related performance and endangering a patient’s social status.

Key words

thyroid autoimmunity - thyroiditis autoimmunity - thyrotropin hormones
 

  • References

  • 1 Chiovato L, Pinchera A. Stressful life events and Graves’ disease. Eur J Endocrinol 1996; 134: 680-682
    CrossrefPubMedGoogle Scholar
  • 2 Kun AWC. Life events, daily stresses and coping in patients with Graves’ disease. Clin Endocrinol 1995; 42: 303-308
    CrossrefPubMedGoogle Scholar
  • 3 Samuels MH, Schuff KG, Carlson NE et al. Health Status, Mood, and Cognition in Experimentally Induced Subclinical Thyrotoxicosis. J Clin Endocrinol Metab 2008; 93: 1730-1736
    CrossrefPubMedGoogle Scholar
  • 4 Gulseren S, Gulseren L, Hekimsoy Z et al. Depression, anxiety, health-related quality of life, and disability in patients with overt and subclinical thyroid dysfunction. Arch Med Res 2006; 37: 133-139
    CrossrefPubMedGoogle Scholar
  • 5 Röckel M, Teuber J, Schmidt R et al. Correlation of “latent hyperthyroidism” with psychological and somatic changes. Klin Wochensch 1987; 65: 264-273
    CrossrefPubMedGoogle Scholar
  • 6 Bommer M, Eversmann T, Pickardt R et al. Psychopathological and neuropsychological symptoms in patients with subclinical and remitted hyperthyroidism. Klin Wochenschr 1990; 68: 552-558
    CrossrefPubMedGoogle Scholar
  • 7 Sait Gonen M, Kisakol G, Savas Cilli A et al. Assessment of anxiety in subclinical thyroid disorders. Endocr J 2004; 51: 311-315
    CrossrefPubMedGoogle Scholar
  • 8 Biondi B, Palmieri EA, Fazio S et al. Endogenous subclinical hyperthyroidism affects quality of life and cardiac morphology and function in young and middle-aged patients. J Clin Endocrinol Metab 2000; 85: 4701-4705
    CrossrefPubMedGoogle Scholar
  • 9 Bianchi GP, Zaccheroni V, Solaroli E et al. Health-related quality of life in patients with thyroid disorders. Qual Life Res 2004; 13: 45-54
    CrossrefPubMedGoogle Scholar
  • 10 Abraham-Nordling M, Wallin G, Lundell G et al. Thyroid hormone state and quality of life at long-term follow-up after randomized treatment of Graves’ disease. Euro J Endocrinol 2007; 156: 173-179
    CrossrefPubMedGoogle Scholar
  • 11 Chen CH. Symptom Checklist 90 (SCL-90). In: Wang XD, Wang XL, Ma H. Rating Scales for Mental Health. Chinese Mental Health Journal. 1999. S31–S35 in Chinese
    Google Scholar
  • 12 Gong YX. Eysenck Personality Quesationnaire-R Short Scale Chinese, EPQ-RSC. Changsha: Hunan Medical University; 1983
    Google Scholar
  • 13 Xie YN. Simplified Coping Style. Chinese Mental Health Journal 1999; 122-124 in Chinese
    PubMedGoogle Scholar
  • 14 Folkman S, Lazarus RS. An analysis of coping in a middle-aged community sample. J Health Soc Behav 1980; 21: 219-239
    CrossrefPubMedGoogle Scholar
  • 15 Yang DS, Zhang YL. Life Event Scale (LES). Chinese Mental Health Journal 1999; 101-106 in Chinese
    PubMedGoogle Scholar
  • 16 Holmes TH, Rahe RH. The Social Readjustment Rating Scale. J Psychosom Res 1967; 11: 213-218
    CrossrefPubMedGoogle Scholar
  • 17 Jiang QJ. Perceived Social Support Scale (PSSS). Chinese Mental Health Journal 1999; 131-133 in Chinese
    PubMedGoogle Scholar
  • 18 Chen DY, Jing J, Schneider PF et al. Comparison of the long-term efficacy of low dose 131I versus antithyroid drugs in the treatment of hypothyroidism. Nucl Med Commun 2009; 30: 160-168
    CrossrefPubMedGoogle Scholar
  • 19 Chen DY, Chen TH. Mental Health Status and Its Influencing Factors in Hyperthyroid Patients. Chinese Mental Health Journal 2006; 20: 820-823 in Chinese
    PubMedGoogle Scholar
  • 20 Jin H, Wu WY, Zhang MY. Primary analysis of the assessment results for normal Chinese adults with SCL-90. Chinese Journal of Nervous and Mental Diseases 1986; 12: 260-263 in Chinese
    PubMedGoogle Scholar
  • 21 Fahrenfort JJ, Wilterdink AM, van der Veen EA. Long-term residual complaints and psychosocial sequelae after remission of hyperthyroidism. Psychoneuroendocrinology 2000; 25: 201-211
    CrossrefPubMedGoogle Scholar
  • 22 Winsa B, Adami HO, Bergström R et al. Stressful life events and Graves’ disease. Lancet 1991; 338: 1475-1479
    CrossrefPubMedGoogle Scholar
  • 23 Yoshiuchi K, Kumano H, Nomura S et al. Psychosocial factors influencing the short-term outcome of antithyroid drug therapy in Graves’ disease. Psychosomatic Medicine 1998; 60: 592-596
    PubMedGoogle Scholar
  • 24 Simon NM, Blacker D, Korbly NB et al. Hypothyroidism and hyperthyroidism in anxiety disorders revisited: new data and literature review. J Affect Disord 2002; 69: 209-217
    CrossrefPubMedGoogle Scholar
  • 25 Trzepacz PT, Klein I, Roberts M et al. Graves’ disease: an analysis of thyroid hormone levels and hyperthyroid signs and symptoms. Am J Med 1989; 87: 558-561
    CrossrefPubMedGoogle Scholar
  • 26 Paschke R, Harsch I, Schlote B et al. Initial psychological testing during the course of autoimmune hyperthyroidism. Klin Wochenschr 1990; 68: 942-950
    CrossrefPubMedGoogle Scholar
  • 27 Schlote B, Schaaf L, Schmidt R. Mental and physical state in subclinical hyperthyroidism: investigations in a normal working population. Biol Psychiatry 1992; 32: 48-56
    CrossrefPubMedGoogle Scholar
  • 28 Fukao A, Takamatsu J, Murakami Y et al. The relationship of psychological factors to the prognosis of hyperthyroidism in antithyroid drug-treated patients with Graves’ disease. Clin Endocrinol 2003; 58: 550-555
    CrossrefPubMedGoogle Scholar
  • 29 Stern RA, Robinson B, Thorner AR. A survey study of neuropsychiatric complaints in patients with Graves’ disease. J Neuropsychiatry Clin Neurosci 1996; 8: 181-185
    PubMedGoogle Scholar